Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jan 16;15(1):1.
doi: 10.1186/1532-429X-15-1.

Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy

Alessia Pepe  1 , Antonella Meloni, Giuseppe Rossi, Liana Cuccia, Giuseppe Domenico D'Ascola, Michele Santodirocco, Paolo Cianciulli, Vincenzo Caruso, Maria Antonietta Romeo, Aldo Filosa, Lorella Pitrolo, Maria Caterina Putti, Angelo Peluso, Saveria Campisi, Massimiliano Missere, Massimo Midiri, Letizia Gulino, Vincenzo Positano, Massimo Lombardi, Paolo Ricchi
Affiliations
Comparative Study

Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy

Alessia Pepe et al. J Cardiovasc Magn Reson. .

Abstract

Background: Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months.

Methods: Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74) monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images.

Results: The percentage of patients that maintained a normal global heart T2* value was comparable between DFP+DFO versus both monotherapy groups. Among the patients with myocardial iron overload at baseline, the changes in the global heart T2* and in biventricular function were not significantly different in DFP+DFO compared with the DFP group. The improvement in the global heart T2* was significantly higher in the DFP+DFO than the DFO group, without a difference in biventricular function. Among the patients with hepatic iron at baseline, the decrease in liver iron concentration values was significantly higher with combination therapy than with either monotherapy group.

Conclusions: In TM patients at the dosages used in the real world, the combined DFP+DFO regimen was more effective in removing cardiac iron than DFO, and was superior in clearing hepatic iron than either DFO or DFP monotherapy. Combined therapy did not show an additional effect on heart function over DFP.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The patient flow.
Figure 2
Figure 2
Intra-treatment comparison between final and basal values for heart iron and function in patients with basal global heart T2* value < 20 ms.
Figure 3
Figure 3
Inter-treatment and inter-treatment comparisons between final and basal values for MRI LIC values in patients with basal MRI LIC > 3 mg/g/dw.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in Deferoxamine- or Deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733–3737. doi: 10.1182/blood-2005-07-2933. - DOI - PubMed
    1. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA. et al.Randomized controlled trial of Deferiprone or Deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–3744. doi: 10.1182/blood-2005-07-2948. - DOI - PubMed
    1. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, de Marchi D, Midiri M, Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006;76:183–192. doi: 10.1111/j.1600-0609.2005.00587.x. - DOI - PubMed
    1. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with Deferoxamine and Deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884. doi: 10.1161/CIRCULATIONAHA.106.648790. - DOI - PubMed
    1. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12. doi: 10.1186/1532-429X-10-12. - DOI - PMC - PubMed

Publication types

MeSH terms